Taken together, investigating the specific role of FGF10 and its receptor FGFR2B in IPF may help create effective anti-fibrotic FGF10-based therapies that precisely target this signaling pathway with optimal efficacy. This evidence concerns the gene FGF10 and idiopathic pulmonary fibrosis.